WHAT WE DELIVER
Focused on significant unmet medical needs, leveraging established expertise in rare diseases, dermatology, and CNS disorders
WHAT WE DO
Drug Repurposing
We develop innovative therapeutics by repositioning approved drugs for new indications, utilizing novel formulations or prodrug designs through the US FDA’s 505(b)(2) regulatory pathway: New Indications: AC-203, New Formulations: AC-203 , AC-1101, Prodrugs: Nora520.
New drug in development
0
Partnerships
0
Geography of Clinical Studies
0
WHAT’S NEW
Staying up to date with our latest developments
We keep our stakeholders informed by providing timely updates on our R&D endeavors, clinical trial progress, regulatory milestones, commercial partnerships, financing activities, and corporate actions, etc.
Feb
05
Press Release．2026
Announces Interim Analysis Results from the Global Phase 2/3 Clinical Trial of AC-203 for the Treatment of Epidermolysis Bullosa Simplex (EBS)
Dec
27
Events．2025
Beyond Pain, Empowering Voices: Advancing Innovation for Rare Disease Care
Nov
20
Press Release．2025
Our Deepest Appreciation to All Shareholders Who Stand Behind Us.
Nov
16
Press Release．2025
Key Efficacy Results of NORA520 Phase II Clinical Trial for the Treatment of Postpartum Depression (PPD)
What are you looking for today?
Quick Links
ESG
From environmental protection and social care to transparent governance, we practice responsible management to create shared prosperity for business and society.
Investors
We continue to deliver on expectations through evidence-based results, sustainable development, and transparent governance. We invite you to join us in witnessing our growing impact.
Working at TWiB
Join us at the forefront of drug development, clinical advancement, and global collaboration—and help create impact that truly matters to society.